FDA Oncology Announcements

Anti-FOLR1 ADC × Gynecologic × Clear all

2 Announcements

FDA approves mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Trial: MIRASOL
Drug: Elahere (mirvetuximab soravtansine-gynx) · Anti-FOLR1 antibody-drug conjugate
Condition: Gynecologic

FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer

Trial: SORAYA
Drug: Elahere (mirvetuximab soravtansine-gynx) · Anti-FOLR1 antibody-drug conjugate
Condition: Gynecologic